Inhibikase Therapeutics Investor Relations Material

Inhibikase Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of therapeutics for neurological disorders associated with genetic mutations and protein-protein interactions. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain; IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers; and Ibuprofen Knee Pain, Pain Relief Capsules. It also has programs underway for other neurological diseases such as Duchenne Muscular Dystrophy (DMD), Friedreich Ataxia, and Alzheimer's disease.